ESPR

Esperion Therape

2.700

-0.340-11.18%

After Hours: 2.730 +0.030 +1.10%19:44 03/10 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.120/3.040

TODAY RANGE2.660-3.270

VOL10.08M

MARKET CAP645.47M

52 WEEK RANGE0.6925-4.175

AVG VOL (3M)5.00M

% TURNOVER4.21%

TURNOVER--

P/E (TTM)-5.0392

% RANGE20.07%

EPS(TTM)-0.5358

P/E(FORWARD)-45.0000

P/B-1.2288

BVPS-2.1972

DIVIDEND--

P/S1.591

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP617.56M

SHARES OUTSTANDING239.06M

NEXT EARNINGS03/02-03/06

FREE FLOAT228.73M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·6h ago
Analysts Are Bullish on These Healthcare Stocks: Tenax Therapeutics (TENX), Esperion (ESPR)
Reuters·7h ago
BUZZ-U.S. STOCKS ON THE MOVE-GE Vernova, Atlas Energy, Citigroup
TipRanks·8h ago
Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating
Reuters·9h ago
BUZZ-Esperion falls after quarterly results miss estimates
Seeking Alpha·9h ago
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio
TipRanks·11h ago
Options Volatility and Implied Earnings Moves Today, March 10, 2026
NASDAQ·12h ago
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
Reuters·13h ago
Esperion Therapeutics Q4 revenue jumps 144% on US product strength
Seeking Alpha·13h ago
Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M
TipRanks·13h ago
Esperion reports Q4 EPS 22c, consensus 28c
TipRanks·13h ago
Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025
Dow Jones·13h ago
*Esperion Therapeutics Sees 2026 Operating Expenses in $225M-$255M Range >ESPR
Reuters·13h ago
Esperion Q4 total revenue more than doubled to USD 168.4 million as U.S. net product revenue rose 38% to USD 43.7 million
Reuters·13h ago
BRIEF-Esperion Therapeutics Q4 Product Sales USD 43.723 Million

Same Industry

Name/Symbol

Change%

Price

ESPR

McKesson

MCK

+2.49%

942.16

BIIB

Amgen Inc

AMGN

+0.53%

369.53

Shire

SHPG

0.00%

179.20

CELG-RT

LLY

CELG

TXMD

Johnson & Johnson

JNJ

+0.32%

240.40

Abbvie Inc

ABBV

-0.96%

230.11

Zoetis Inc

ZTS

-0.65%

121.43

Gilead Sciences Inc

GILD

+1.32%

148.56

Novo-Nordisk A/S

NVO

-1.25%

38.58

Bristol-Myers Squibb Co

BMY

-0.74%

60.29

PFE

ALXN

Sanofi FR

SNY

-1.00%

44.55

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-0.55%

160.12

RDY

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.